1. Home
  2. ASBP vs PMCB Comparison

ASBP vs PMCB Comparison

Compare ASBP & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aspire Biopharma Holdings Inc.

ASBP

Aspire Biopharma Holdings Inc.

HOLD

Current Price

$0.57

Market Cap

7.6M

Sector

Health Care

ML Signal

HOLD

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

HOLD

Current Price

$0.72

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASBP
PMCB
Founded
2021
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6M
8.3M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
ASBP
PMCB
Price
$0.57
$0.72
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
155.7K
121.4K
Earning Date
03-31-2026
03-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
277.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$0.63
52 Week High
$2.45
$1.70

Technical Indicators

Market Signals
Indicator
ASBP
PMCB
Relative Strength Index (RSI) 26.74 48.51
Support Level $0.32 $0.65
Resistance Level $0.88 $0.77
Average True Range (ATR) 0.15 0.06
MACD -0.09 0.01
Stochastic Oscillator 3.13 51.18

Price Performance

Historical Comparison
ASBP
PMCB

About ASBP Aspire Biopharma Holdings Inc.

Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Share on Social Networks: